CTOs on the Move

Oncorus

www.oncorus.com

 
Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded by well-known biotechnology entrepreneurs and is backed by MPM Capital. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world. We are located in Kendall Square, Cambridge, MA.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.oncorus.com
  • 450 Kendall St 4th Floor
    Cambridge, MA USA 02142
  • Phone: 857.320.6402

Executives

Name Title Contact Details

Funding

Oncorus raised $57M on 07/20/2016
Oncorus raised $61M on 12/16/2016
Oncorus raised $79.5M on 08/21/2019
Oncorus raised $57M on 02/12/2021
Oncorus raised $20M on 04/05/2022

Similar Companies

Genesis Therapeutics

Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D.

Skingenix

Skingenix is a Arcadia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DEKA Research and Development Corporation

DEKA Research and Development Corporation is a Manchester, NH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Foxtag Enterprises

Foxtag Enterprises is a Rockledge, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CollabRx

CollabRx is a clinical decision-support company delivering expert solutions in precision oncology that enable physicians, laboratories, payers, and providers to achieve standardized, evidence-based care and superior clinical outcomes. CollabRx uses information technology to aggregate and contextualize the world`s knowledge on genomics-based medicine with specific insights from the nation`s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care.